Nutrition News

Findings recently published in the American Journal of Kidney Diseases suggested that individuals who reported drinking greater amounts of coffee per day were at lower risk for incident chronic kidney disease after researchers adjusted for appropriate covariates.

DaVita Kidney Care recently honored its more than 2,000 registered dietitians across the United States and in 11 countries around the world on Registered Dietitian Nutritionist Day.

Researchers from The George Institute for Global Health at the University of Sydney reported that BMI can be a predictor of developing end-stage renal disease among patients with type 2 diabetes.

Patients with progressive kidney disease may experience the same medicinal benefits of consuming caffeinated drinks as the general population, according to data recently presented at Kidney Week 2017.

New Orleans - AstraZeneca’s investigational hyperkalemia treatment sodium zirconium cyclosilicate (ZS-9) reduced serum potassium levels in patients with hyperkalemia and maintained blood serum potassium at normal levels (normokalemia) for up to 12 months, according to data from a Phase 3 open label trial examining long-term safety and efficacy. The data was presented by lead investigator Steven Fishbane, MD, from Hofstra Northwell School of Medicine, at the American Society of Nephrology's Kidney Week 2017.

The U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Keryx Biopharmaceuticals Inc.’s Auryxia (ferric citrate) tablets. The Prescription Drug User Fee Act target action date for completion of the FDA’s review is Nov. 6, 2017.

The U.S. Food and Drug Administration has accepted for review AstraZeneca’s re-submission of a new drug application for the hyperkalemia drug sodium zirconium cyclosilicate (ZS-9). The FDA has indicated that this is a complete class 2 response.

Introduction

I spoke with Debbie Benner, MA, RD, CSR, Vice President of Clinical Support and Patient Alignment at DaVita HealthCare Partners Inc. about how the integrated care model affects renal dietitians and their patients.

Keryx Biopharmaceuticals Inc. said ferric citrate met the goals of a Phase 3 study to treat iron deficiency anemia in adults with stage 3-5 non-dialysis dependent chronic kidney disease.